Keflex is approved for treatment of respiratory tract infections caused by S. pneumoniae and S. pyogenes; otitis media due to S. pneumoniae, H. influenzae, and M. catarrhalis; and skin and soft tissue infections due to staphylococci and/or streptococci as well as several other bacterial infections.
Keflex Powder is now available in 125 mg/5 mL and 250 mg/5 mL strengths in two bottle sizes, 100ml and 200ml.
“We are pleased to offer Keflex to customers once again. Pediatricians and parents understand how challenging it can be to administer antibiotic therapy to pediatric patients. We are hopeful that the appealing flavor of Keflex will improve patient cooperation and compliance,” stated Darren Buchwald, Advancis vice president, marketing.
Advancis acquired Keflex from Eli Lilly in July 2004. The product launch completes the process it has been working on to commercialize an oral form of the drug.